This program will provide general information regarding dementia-related hallucinations and delusions and will discuss a proposed neural pathway that may be associated with them. Additionally, the unmet need for the treatment of dementia-related hallucinations and delusions will be discussed, with a particular focus on the risk/benefit ratio of current atypical antipsychotics. This disease awareness, non-CME presentation is intended only for US healthcare professionals involved in the management of people with dementia-related hallucinations and delusions and is sponsored by Acadia Pharmaceuticals Inc. This program is not meant to discuss specific treatment options for dementia-related psychosis.

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.